Q1 FY27 results: PAT declines 24.5% YoY to Rs 588.56 lakh

Ebitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.4%Reaction day

₹1138.50

prior close

₹1090.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-6.4% vs market

Pharmaceuticals peers, median of 168sector+0.3%-6.6% vs sector

On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.5

10m

-4.6

15m

-4.6

30m

-4.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.4+0.0-6.4+0.3-6.6

Next day

-6.7-0.0-6.6+0.7-7.4

-6.5-0.2-6.3+0.6-7.0

-6.1+0.2-6.3+0.4-6.5

-6.9+0.3-7.3+1.2-8.1

-6.6+0.4-7.0+0.2-6.8

—+0.9—+0.2—

15d

—+1.6—+1.1—

—+2.0—+2.4—

—+0.6—+1.6—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Revenue from operations was nearly flat at Rs 3,551.20 lakh versus Rs 3,552.68 lakh in Q1 FY26. Profit after tax fell 24.5% YoY to Rs 588.56 lakh from Rs 779.18 lakh, with EPS at Rs 13.34 versus Rs 17.66. Employee expenses jumped to Rs 1,302.52 lakh from Rs 1,172.08 lakh. No exceptional items this quarter versus Rs 395.11 lakh labour codes charge in Q4 FY26.

Likely market impact

Margins shrank and staff costs rose, pulling profit lower on flat revenue. Weak quarter for shareholders.